false
--04-30
0001157075
0001157075
2026-11-10
2026-11-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of
earliest event reported): November 10,
2026
PHARMACYTE
BIOTECH, INC.
(Exact Name of Registrant as Specified in its Charter)
| Nevada |
001-40699 |
62-1772151 |
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
3960
Howard Hughes Parkway, Suite
500 Las
Vegas,
Nevada |
89169 |
| (Address of Principal Executive Offices) |
(Zip Code) |
Registrant's telephone number, including area code:
(917) 595-2850
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of exchange on which registered |
| Common Stock, Par Value $0.0001 Per Share |
|
PMCB |
|
The Nasdaq
Stock Market LLC |
| |
|
|
|
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.03 Material Modification to Rights of Security
Holders.
To the extent required by Item
3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference.
Item 5.03 Amendments to Articles of Incorporation
or Bylaws; Change in Fiscal Year.
On November 10, 2026, PharmaCyte
Biotech, Inc., a Nevada corporation (the “Company”), filed with the Secretary of State of the State of Nevada a certificate
of amendment (the “Certificate of Amendment”) to its Articles of Incorporation, as amended, to effect a reverse stock split
of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of 1-for-19 (the “Reverse
Stock Split”), with an effective date of November 12, 2026. The Reverse Stock Split was approved by the Company’s stockholders
at the Company’s annual meeting of stockholders held on March 30, 2026, which authorized the Company’s board of directors
to effect a reverse stock split at a ratio between 1-for-1.1 and 1-for-100. Pursuant to the Certificate of Amendment, the Reverse Stock
Split became effective as of 4:01 p.m. Eastern Time on November 12, 2026 (the “Effective Time”), and the Common Stock began
trading on a split-adjusted basis at the open of trading on The Nasdaq Capital Market on November 13, 2026. At the Effective Time, every
nineteen (19) shares of the Company’s issued and outstanding Common Stock were automatically combined and converted into one (1)
share of Common Stock, without any change in the par value per share. In addition, proportionate adjustments were made to the per share
exercise price and the number of shares issuable upon the exercise of all outstanding stock options, warrants and convertible securities,
and to the number of shares issued and issuable under the Company’s equity incentive plans. No change was made to the number of
shares of Common Stock authorized under the Company’s Articles of Incorporation, as amended. Any stockholder who would otherwise
be entitled to a fractional share of Common Stock created as a result of the Reverse Stock Split is entitled to receive a cash payment
in lieu thereof equal to the fractional share to which the stockholder would otherwise be entitled multiplied by the closing sales price
of a share of Common Stock on The Nasdaq Capital Market on the trading day immediately prior to the Effective Time, as adjusted for the
Reverse Stock Split.
Following the Reverse Stock Split,
the shares of Common Stock continue to trade on The Nasdaq Capital Market under the symbol “PMCB.” The new CUSIP number for
the Common Stock following the Reverse Stock Split is 71715X302.
The foregoing description of
the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate
of Amendment, a copy of which is attached as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 8.01 Other Events.
On November 11, 2026, the Company
issued a press release announcing the Reverse Stock Split. The press release is attached hereto as Exhibit 99.1 and incorporated herein
by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. |
|
Description |
| 3.1 |
|
Certificate of Amendment to the Articles of Incorporation, as amended, of PharmaCyte Biotech, Inc. |
| 99.1 |
|
Press Release issued by PharmaCyte Biotech, Inc., dated November 11, 2026. |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
| |
|
|
| |
PHARMACYTE BIOTECH, INC. |
| |
|
| Date: November 13, 2026 |
|
| |
|
|
| |
By: |
/s/ Joshua N. Silverman |
| |
Name: |
Joshua N. Silverman |
| |
Title: |
Chief Executive Officer and President |
Exhibit 99.1
PharmaCyte Biotech, Inc.
Announces Reverse Stock Split
PharmaCyte’s common stock is expected to begin
trading on a post-split adjusted basis on November 13, 2026
LAS VEGAS--(BUSINESS WIRE)—November 11, 2026—PharmaCyte
Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced that the board of directors of the
Company approved a 1-for-19 reverse stock split (the “Reverse Split”) of the Company’s common stock. The Reverse Split
was approved by the stockholders at the Company’s annual meeting of the stockholders held on March 30, 2026. The Reverse Split will
legally take effect at 4:01 p.m. Eastern Time, on November 12, 2026. The Company’s common stock will open for trading under a new
CUSIP number 71715X 302 on The Nasdaq Capital Market on November 13, 2026, on a split-adjusted basis under the current ticker symbol “PMCB.”
The Reverse Split is intended to increase the per share trading price of the Company’s common stock to enable the Company to regain
compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
The 1-for-19 Reverse Split
will automatically convert every nineteen (19) current shares of the Company’s common stock into one (1) share of common stock.
No fractional shares will be issued in connection with the Reverse Split. Stockholders who would otherwise hold a fractional share of
the Company’s common stock following the Reverse Split will receive a cash payment in lieu thereof equal to the fractional share
to which the stockholder would otherwise be entitled multiplied by the closing sales price of a share of the Company’s common stock
on The Nasdaq Capital Market, on November 12, 2026 (the last trading day prior to the commencement of split-adjusted trading), as adjusted
for the Reverse Split
The Reverse Split will reduce
the number of shares of outstanding common stock from approximately 10,755,649 shares, the number of shares outstanding as of November
11, 2026, to approximately 566,087 shares. The total authorized number of shares will not be reduced. Proportional adjustments will also
be made to the exercise and conversion prices of the Company’s outstanding stock options, warrants and convertible securities, and
to the number of shares issued and issuable under the Company’s stock incentive plans.
Stockholders holding their
shares electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares
through a bank, broker, or other nominee will have their positions automatically adjusted to reflect the Reverse Split, subject to brokers’
particular processes, and will not be required to take any action in connection with the Reverse Split. For those stockholders holding
physical stock certificates, the Company’s transfer agent, Equiniti Trust Company, LLC, will send instructions for exchanging those
certificates for shares held electronically in book-entry form or for new certificates, in either case representing the post-split number
of shares, and any payments in cash in lieu of fractional shares, if applicable.
Forward Looking Statements
Any statements in this press release about our future
expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, the
timing and effectiveness of the Reverse Split, the Company’s ability to regain compliance with the Nasdaq minimum bid price and
other listing requirements and other statements containing the words “believes,” “anticipates,” “plans,”
“expects,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various
important factors, including statements regarding the Company’s current objectives. These statements are based on the Company’s
current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements,
whether as a result of new information, future events, or otherwise, except as required by law. Additional information regarding these
and other risks and uncertainties is contained in the Company’s filings with the Securities and Exchange Commission, including the
Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
Investor Contact:
CORE IR
ir@pharmacyte.com
Media Contact:
Jules Abraham
CORE IR
Telephone: 917.885.7378
Email: julesa@coreir.com